UroGen Pharma Ltd. Deferred Tax Liabilities, Leasing Arrangements
UroGen Pharma Ltd. (URGN) had Deferred Tax Liabilities, Leasing Arrangements of $1.90 million as of 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Liabilities, Gross
us-gaap:DeferredTaxLiabilitiesLeasingArrangements · last filed 2026-03-02
- 2025-12-31: Deferred Tax Liabilities, Leasing Arrangements $1.90M.
- 2024-12-31: Deferred Tax Liabilities, Leasing Arrangements $725.00K.
- 2023-12-31: Deferred Tax Liabilities, Leasing Arrangements $276.00K.
| Period end | Deferred Tax Liabilities, Leasing Arrangements |
|---|---|
| 2025-12-31 | $1.90M 10-K · filed 2026-03-02 |
| 2024-12-31 | $725.00K 10-K · filed 2026-03-02 |
| 2023-12-31 | $276.00K 10-K · filed 2025-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |